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Case ReportsSevere bleeding as a result of platelet inhibition caused by floxacillin
treatment for endocarditisJuliane Rau, MD, Mark Simon, MD, Michael Sander, MD, PhD, and
Christian von Heymann, MD, PhD, DEAA, Berlin, GermanyIn infectious endocarditis, antibiotic treatment is the
cornerstone of medical therapy and may be amended by
removal of the infected cardiac device when indicated.1
As rates of endocarditis associated with pacemaker
and implantable cardioverter-defibrillator (ICD) implants
increase, drug interactions and rare side effects of anti-
biotics may become more frequent.
Isoxazolyl penicillins such as floxacillin (INN flucloxa-
cillin) are recommended for antibiotic therapy in endocardi-
tis caused by methicillin-sensitive Staphylococcus aureus.
Inhibited platelet aggregation has been reported for some
penicillins,2-4 but not yet floxacillin. For the first time, we
report high-dose floxacillin-induced inhibition of platelet
aggregation leading to severe bleeding.
CLINICAL SUMMARY
A 62-year-old white man was admitted with multiorgan
failure due to septic shock as a result of ICD lead–associ-
ated right-sided endocarditis. He had a known history of in-
flammatory cardiomyopathy as a result of viral myocarditis
6 years previously, a left ventricular ejection fraction of
30%, intermittent clusters of ventricular tachycardias, un-
successful catheter ablation, and implantation of an ICD
implanted 5 years previously.
After preoperative stabilization, the ICD and leads,
except parts of the lead armor, were surgically removed.
Postoperatively, atrial fibrillation with rapid conduction
was successfully converted into sinus rhythm with an
intravenous loading dose of amiodarone, which was
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The Journal of Thoracic and CaMethicillin-sensitive S aureus was detected in multiple
blood cultures, and resistogram-guided antibiotic treatment
was adjusted to floxacillin, which is in accordance with
national guidelines for methicillin-sensitive S aureus
endocarditis. A duration of at least 3 months of antibiotic
treatment and a dose increase to 12 g daily because of the
indwelling ICD lead armor was agreed on with the
attending microbiologist.
After 4 days of high-dose floxacillin, severe epistaxis
requiring surgical intervention occurred, along with
recurrent bleeding from the bronchial tree, the sternotomy,
and the ICD cavity wound. In addition to inotropic support,
the patient needed transfusions of allogeneic blood products
for maintenance of hemodynamic stability.
Results of conventional laboratory coagulation assays,
rotational thromboelastometry, and the Platelet Function
Analyzer (PFA-100, CAPD and CEPI cartridges; Siemens
Healthcare Diagnostics GmbH, Eschborn, Germany) were
normal, despite aspirin treatment for prevention of myocar-
dial infarction. In the face of ongoing diffuse bleeding,
drug-induced coagulation defects were reconsidered.
Because penicillins2-4 and amiodarone had previously
been reported to cause platelet dysfunction, platelet
function was reassessed with whole-blood impedance
aggregometry (multiple-electrode aggregometry [MEA]
Multiplate; Roche Diagnostics GmbH, Germany, Man-
nheim, Germany). Results of all tests indicated a severe
platelet dysfunction, although overall platelet count was
normal (Figure 1).
Floxacillin and amiodarone were immediately discontin-
ued, and antibiotic treatment was switched to daptomycin.
The bleeding then stopped, and the closely monitored
platelet function revealed a recovery of aggregation despite
ongoing aspirin medication (Table 1).
The recurrence of hemodynamically relevant, malignant
arrhythmias required a resumption of amiodarone treatment
10 days after the first MEA testing. To exclude amiodarone-
and aspirin-induced platelet dysfunction, platelet aggrega-
tion was intermittently monitored for another 2 weeks.
Although aspirin dosage was increased, bleeding did not
recur, nor did MEA results (adenosine diphosphate [ADP]
and thrombin receptor–activating peptide) deteriorate again
(Table 1). Retrospective analysis of the onset of bleeding
and concomitant medication demonstrated floxacillin-
associated, dose-dependent platelet dysfunction the most
likely cause of the symptoms.rdiovascular Surgery c Volume 146, Number 6 e63
FIGURE 1. Initial results of multiple electrode aggregometry (A-C) and
platelet count (D) for the patient treated with high-dose floxacillin,
amiodarone, and 100 mg aspirin. Reference ranges are as follows:
Thrombin receptor–activating peptide (TRAP) test, 84-128 units; aspirin-
sensitive patient identification (ASPI) test, 71-115 units; adenosine
diphosphate (ADP) test, 57-113 units; and platelet count, 150-400 3 109
cells/L. AU, Arbitrary units.
TABLE 1. Course of the patient’s results of multiple-electrode
aggregometry and platelet count measurements after discontinuation
of both floxacillin and amiodarone (days 0-10) and during ongoing
daptomycin, amiodarone, and aspirin treatment (days 10-27)
TRAP test
(units)
ASPI test
(units)
ADP test
(units)
Platelet count
(cells/nL)
Reference
range
84-128 71-115 57-113 150-400
Day 0 41 9 37 306
Day 4 65 5 53 399
Day 5 74 6 61 424
Day 6 124 16 91 461
Day 7 82 11 80 424
Day 12 127 61 130 428
Day 15 117 91 102 468
Day 17 102 54 104 441
Day 19 103 11 117 504
Day 21 160 48 86 394
Day 23 120 48 75 317
Day 25 99 20 65 285
Day 27 101 10 69 273
TRAP, Thrombin receptor–activating peptide; ASPI, aspirin-sensitive patient identifi-
cation; ADP, adenosine diphosphate.
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e64 The Journal of Thoracic and Cardiovascular SurgThe publication of this case was approved by the institu-
tional review board (Ethikkommission, Charite–University
Medicine Berlin, EA1/074/12). Informed consent for
publication was given both orally by the patient and also
as written by the legal guardian.
DISCUSSION
This case report describes severe bleeding caused by
inhibited platelet aggregation related to high-dose flox-
acillin. An earlier case report described high-dose
penicillin-induced hemorrhages that stopped after discon-
tinuation of antibiotic treatment.3 In a patient with
high-dose penicillin treatment, MEA measurements
revealed significantly inhibited platelet aggregation,
comparable to that seen with dual antiplatelet medication.3
As in our case, the change of the antibiotic resulted in the
recovery of platelet function, as measured by MEA.
In the case presented here, inhibition of platelet aggrega-
tion was diagnosed by MEA despite normal PFA-100
findings. MEA specifically assesses platelet aggregation
by the inhibition of cyclooxygenase, ADP, and glycoprotein
IIb/IIIa receptors, depending on the activator used, whereas
the PFA-100 system with CEPI or CAPD cartridges
investigates platelet adhesion after activation by collagen
and epinephrine (CEPI) or collagen and ADP (CAPD) in
addition to shear stress. Neither CEPI nor CAPD cartridges
can sensitively assess the effects of ADP receptor
antagonists.
To date, the mechanisms found to be involved in
penicillin-induced platelet dysfunction are time4 and dose
dependent2 inhibition of agonist binding to membraneery c December 2013
Case Reportsreceptors,2,4 inhibition of thromboxane production,4 and
inhibition of agonist-induced calcium influx.4 A genetic
predisposition toward floxacillin-associated side effects5
cannot be excluded but has not been further investigated.
The case presented here represents a severely inhibited
platelet aggregation for high-dose floxacillin, comparable
to ADP receptor blockade plus impaired thrombin
activation, resulting in severe bleeding that resolved after
discontinuation of floxacillin treatment. Inhibition of
platelet aggregation by amiodarone cannot be excluded
completely, but this seems to be unlikely because of
amiodarone’s long half-life (as long as 60 days) and the
failure of the resumption of amiodarone to impair the
normalized platelet aggregation.The Journal of Thoracic and CaReferences
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